2026 ICD-10-CM Diagnosis Code C74.00Malignant neoplasm of cortex of unspecified adrenal gland

ICD-10-CM Codes›C00–D49›C73-C75›C74

ICD-10-CM C74.00
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C74.00 is a billable ICD-10-CM diagnosis code for malignant neoplasm of cortex of unspecified adrenal gland. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 643 through 645. Coders also document this condition as adrenal carcinoma. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Endocrine system cancers - adrenocortical.

Code Identity

ICD-10-CM Code
C74.00
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of cortex of unspecified adrenal gland
Short Description
Malignant neoplasm of cortex of unspecified adrenal gland
Same as the full description in the CMS dataset.
Parent Code
C74.0
Malignant neoplasm of cortex of adrenal gland

Code Classification

ChapterC00–D49Neoplasms
SectionC73-C75Malignant neoplasms of thyroid and other endocrine glands
CategoryC74Malignant neoplasm of adrenal gland
This CodeC74.00Malignant neoplasm of cortex of unspecified adrenal gland

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adrenal carcinoma
  • Malignant neoplasm of adrenal cortex
  • Primary adrenal cortical carcinoma
  • Primary malignant neoplasm of adrenal cortex
  • Stage I: Tumor confined to gland, 5 cm or less
  • Stage II: Tumor confined to gland, greater than 5 cm
  • Stage III: Extraglandular extension of tumor without other organ involvement
  • Stage IV: Distant metastasis or extension into other organs

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO053
Endocrine system cancers - adrenocortical
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
adrenal › cortexC74.0C79.7D09.3D35.0D44.1D49.7
cortexC74.0C79.7D09.3D35.0D44.1D49.7
cortex › adrenalC74.0C79.7D09.3D35.0D44.1D49.7
suprarenal › cortexC74.0C79.7D09.3D35.0D44.1D49.7

Patient EducationClinical

Adrenal Gland Cancer

Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C74.00 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
194.0 Malign neopl adrenal
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C74.00Overview

Is C74.00 (Malignant neoplasm of cortex of adrenal gland) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of cortex of unspecified adrenal gland on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C74.00 group to?

When malignant neoplasm of cortex of unspecified adrenal gland is the principal diagnosis on an inpatient stay, it groups to MS-DRG 643, 644, 645, with relative weights from 0.7683 to 1.6461 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C74.00?

Under the General Equivalence Mappings, malignant neoplasm of cortex of unspecified adrenal gland converts to ICD-9-CM 194.0 (malign neopl adrenal). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.